Skip to main content
. Author manuscript; available in PMC: 2020 May 15.
Published in final edited form as: Clin Cancer Res. 2019 Jul 29;25(22):6662–6670. doi: 10.1158/1078-0432.CCR-19-1436

Table 1.

ALK Mutations in Pre- and Post-Lorlatinib Plasma Specimens

Patient Pre-Lorlatinib Plasma ALK Mutations Post-Lorlatinib Plasma ALK Mutations
MGH9200 L1196M L1196M*, G1202R*
MGH9035 G1202R, L1196M, V1180L G1202R*, L1196M*, C1156Y
MGH9118 D1203N D1203N, G1123D
MGH9158 L1196Q^, L1196M^, G1202R^ L1196M
MGH087 G1202R G1202R
MGH9185 G1202R I1171N, D1203N
MGH9027 I1171N I1171N, D1203N
MGH059 E1210K*, I1171N, V1180L, L1196M* E1210K*, L1196M*
MGH9213 L1196M L1196M*, D1203N*
MGH990 G1202R, I1171N I1171N, D1203N
MGH9212 I1171S, F1174L I1171S, G1269A
MGH919 G1202R*, L1196M* G1202R*, L1196M*
MGH9176 G1202R G1202R
MGH915 None None
MGH964 None None

Blue=mutation only seen in pre-lorlatinib specimen; Red=mutation only seen in post-lorlatinib specimen

*

ALK mutations occurred in cis

^

ALK mutations occurred in trans